FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps

The U.S. Food and Drug Administration has highlighted a recall of duloxetine, drawing attention to persistent quality gaps in generic drug manufacturing. This development serves as a reminder of the regulatory pressures facing generic producers to ensure consistency and safety in their production processes. The situation is significant for the pharmaceutical industry as it emphasizes the potential risks associated with manufacturing oversight in the generic market.